These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33290361)

  • 21. Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.
    Meerveld-Eggink A; Rozeman EA; Lalezari F; van Thienen JV; Haanen JBAG; Blank CU
    Ann Oncol; 2017 Apr; 28(4):862-867. PubMed ID: 28158487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usage of nivolumab and ipilimumab for recurrent or advanced malignant vaginal melanoma: a two-case series.
    Konishi K; Okamoto M; Tokumitsu R; Yano M; Nasu K; Kobayashi E
    Med Mol Morphol; 2024 Jun; 57(2):83-90. PubMed ID: 38289480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
    Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
    Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Advances in immunotherapy for metastatic melanoma].
    Oláh J
    Magy Onkol; 2017 Jun; 61(2):132-136. PubMed ID: 28585614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
    Shoushtari AN; Friedman CF; Navid-Azarbaijani P; Postow MA; Callahan MK; Momtaz P; Panageas KS; Wolchok JD; Chapman PB
    JAMA Oncol; 2018 Jan; 4(1):98-101. PubMed ID: 28817755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
    McDonald MA; Sanghvi P; Bykowski J; Daniels GA
    BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution.
    Vila CM; Moreno FA; Estébanez MM; Ares GR; Villacampa G; Dashti P; Oberoi HS; Martin-Huertas R; Jares P; Alos L; Teixido C; Rull R; Sanchez M; Malvehy J; Carcelero E; Valduvieco I; Fernandez AA
    Clin Transl Oncol; 2022 Feb; 24(2):319-330. PubMed ID: 34420138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin.
    Jain V; Mohebtash M; Rodrigo ME; Ruiz G; Atkins MB; Barac A
    J Immunother; 2018 Sep; 41(7):332-335. PubMed ID: 29965858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study.
    Ibrahim T; Mateus C; Baz M; Robert C
    Cancer Immunol Immunother; 2018 Oct; 67(10):1571-1578. PubMed ID: 30056599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma].
    Tietze JK; Heppt M; Angelova D; Ruzicka T; Berger F; Berking C
    Hautarzt; 2017 Aug; 68(8):632-638. PubMed ID: 28382381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.
    Baron K; Moser JC; Patel S; Grossmann KF; Colonna SV; Hyngstrom JR
    J Oncol Pharm Pract; 2021 Apr; 27(3):555-559. PubMed ID: 32423325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.
    Mineiro Dos Santos Garrett NF; Carvalho da Costa AC; Barros Ferreira E; Damiani G; Diniz Dos Reis PE; Inocêncio Vasques C
    PLoS One; 2021; 16(8):e0255716. PubMed ID: 34358260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018.
    Board R; Smittenaar R; Lawton S; Liu H; Juwa B; Chao D; Corrie P
    Int J Cancer; 2021 Feb; 148(4):868-875. PubMed ID: 32838478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
    Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
    Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Widespread vitiligo and poliosis following ipilimumab-nivolumab combination therapy.
    Nemovi K; Jamali A; Matinpour K; Dasanu CA
    J Oncol Pharm Pract; 2023 Jul; 29(5):1278-1282. PubMed ID: 36785936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study.
    Saijo K; Imai H; Ouchi K; Okada Y; Sato Y; Komine K; Takahashi M; Takahashi S; Shirota H; Takahashi M; Ishioka C
    Tohoku J Exp Med; 2019 May; 248(1):37-43. PubMed ID: 31105123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.
    Postow MA; Knox SJ; Goldman DA; Elhanati Y; Mavinkurve V; Wong P; Halpenny D; Reddy SK; Vado K; McCabe D; Ramirez KA; Macri M; Schwarzenberger P; Ricciardi T; Ryan A; Venhaus R; Momtaz P; Shoushtari AN; Callahan MK; Chapman PB; Wolchok JD; Subrahmanyam PB; Maecker HT; Panageas KS; Barker CA
    Clin Cancer Res; 2020 Jul; 26(13):3193-3201. PubMed ID: 32205463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.